Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maprotiline with Temozolomide and Tamoxifen for Recurrent Glioblastoma
NCT04200066Phase 1Withdrawn
- Sponsor
- University of Rochester
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of maprotiline in glioblastoma (GBM), sponsored by University of Rochester. Primary endpoint: Maximum Tolerated Dosing Regimen at 6 months. Planned start Jun 2022; status: withdrawn.
02
Drugs
maprotiline
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04200066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200066.